Structure‐Guided Optimization and Biological Validation of 1,3,4‐Thiadiazole‐Based SIRT2 Inhibitors Reinforcing Channel Entrance Interactions
Ahmet Bugra Aksel, Fikriye Ozgencil, Filiz Bakar‐Ates, Habibe Beyza Gunindi, Alberto Massarotti, Erva Ozkan, Selen Gozde Kaya, Mahmut Gozelle, Yesim Ozkan, Gokcen Eren

TL;DR
This paper describes the design and testing of new SIRT2 inhibitors that show improved activity and biological effects in cancer cells.
Contribution
The study introduces optimized 1,3,4-thiadiazole-based SIRT2 inhibitors with validated antiproliferative effects and binding stability.
Findings
ST132 showed an IC50 of 6.62 µM and increased acetylated α-tubulin in MCF-7 cells.
Docking and MD simulations confirmed the stability and binding interactions of ST132 with SIRT2.
The inhibitors' structural features at the binding site entrance were identified as key for activity.
Abstract
SIRT2, the cytoplasmic member of the sirtuin family, is generally acknowledged to promote cancer and contribute to the progression of various pathologies, including neurodegeneration, inflammation, obesity, and bacterial infection through the deacetylation of target substrates. In our previous efforts we identified potent and highly selective SIRT2 inhibitors with IC50 values in the micromolar range. To further optimize their activity, we performed molecular docking‐guided design and subsequent synthesis of a series of novel 1,3,4‐thiadiazole derivatives. SIRT inhibitory screening identified that ST131 and ST132 achieved moderate inhibitory effects against SIRT2 with IC50 values of 8.95 and 6.62 µM, respectively. Moreover, cellular assays in MCF‐7 breast cancer cells revealed that ST132 has shown an antiproliferative effect, as well as increased acetylated α‐tubulin expression levels,…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSirtuins and Resveratrol in Medicine · Cancer Research and Treatment · Protein Degradation and Inhibitors
